Advertisement

Topics

After years of delays, NICE backs Celgene's Revlimid in first-line MM

07:34 EDT 17 May 2019 | pharmaphorum

After years of delays caused by wrangling over price, NICE has recommended regular NHS funding for Celgene’s Revlimid in combination with dexamethasone, as an option for certain adults with previously untreated multiple myeloma. The final draft gu...

Original Article: After years of delays, NICE backs Celgene's Revlimid in first-line MM

NEXT ARTICLE

More From BioPortfolio on "After years of delays, NICE backs Celgene's Revlimid in first-line MM"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...